Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Endocrine 1CNS 1

Conditions

Glioma 12Brain Neoplasms 8Melanoma 7Neurofibromatosis 1 5Astrocytoma 5Neurofibroma, Plexiform 4Neoplasms 4Glioblastoma 4Oligodendroglioma 3Multiple Myeloma 3Histiocytosis, Langerhans-Cell 3Thyroid Carcinoma, Anaplastic 2Ovarian Neoplasms 2Neurocytoma 2Neuroblastoma 2Meningioma 2Lung Neoplasms 2Leukemia, Myelomonocytic, Juvenile 2Hematologic Neoplasms 2Ganglioneuroma 2Ganglioglioma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Rhabdoid Tumor 1

Interventions

trametinib 1pembrolizumab 1lenvatinib 1dabrafenib 1Nivolumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × trametinib × CNS × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡